Daiichi and AstraZeneca fight back in cancer drug dispute with Seagen

Daiichi Sankyo and AstraZeneca have asked the US District Court for the District of Delaware for a declaration that their breast cancer treatment does not infringe a chemotherapy patent owned by biotechnology company Seagen.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

AstraZeneca to buy Alexion for $39bn

14 December 2020 AstraZeneca has announced it will acquire Boston-based biopharmaceutical company Alexion Pharmaceuticals, in what is potentially the biggest life sciences deal of this year.

Americas

Pyxis secures ADC licence from Pfizer

22 March 2021 Massachusetts-based biotechnology start-up Pyxis Oncology has secured a licensing deal with Pfizer for two of the pharmaceutical giant’s antibody-drug conjugates.

Big Pharma

PTAB grants review of Seagen patent on eve of court’s infringement ruling

11 April 2022 The US Patent Trial and Appeal Board has agreed to review claims of a Seagen patent that Daiichi Sankyo was found to have infringed with its Enhertu breast cancer treatment.

More on this story

Americas

AstraZeneca to buy Alexion for $39bn

14 December 2020 AstraZeneca has announced it will acquire Boston-based biopharmaceutical company Alexion Pharmaceuticals, in what is potentially the biggest life sciences deal of this year.

Americas

Pyxis secures ADC licence from Pfizer

22 March 2021 Massachusetts-based biotechnology start-up Pyxis Oncology has secured a licensing deal with Pfizer for two of the pharmaceutical giant’s antibody-drug conjugates.

Big Pharma

PTAB grants review of Seagen patent on eve of court’s infringement ruling

11 April 2022 The US Patent Trial and Appeal Board has agreed to review claims of a Seagen patent that Daiichi Sankyo was found to have infringed with its Enhertu breast cancer treatment.

More on this story

Americas

AstraZeneca to buy Alexion for $39bn

14 December 2020 AstraZeneca has announced it will acquire Boston-based biopharmaceutical company Alexion Pharmaceuticals, in what is potentially the biggest life sciences deal of this year.

Americas

Pyxis secures ADC licence from Pfizer

22 March 2021 Massachusetts-based biotechnology start-up Pyxis Oncology has secured a licensing deal with Pfizer for two of the pharmaceutical giant’s antibody-drug conjugates.

Big Pharma

PTAB grants review of Seagen patent on eve of court’s infringement ruling

11 April 2022 The US Patent Trial and Appeal Board has agreed to review claims of a Seagen patent that Daiichi Sankyo was found to have infringed with its Enhertu breast cancer treatment.

More features

Chinese biotech takes out US rival’s nucleic acid patent at PTAB

Attorney v examiner: Navigating patenting's AI tools ‘arms race’

Lewis Roca promotes tech expert to managing partner

Panitch Schwarze brings in molecular biologist

US targets ‘product hopping’ with biologic litigation curbs

UPC confirms validity of Edwards Lifesciences heart valve tech patent

ITC concludes row over biotech lab equipment between US and German rivals

UKIPO launches ‘revolutionary’ patent filing and AI tool

Daiichi and AstraZeneca fight back in cancer drug dispute with Seagen

More on this story

Editor's picks

Editor's picks

More on this story

More on this story

More features